Description

Seven companies listing additional securities under ESOP/ESOS schemes effective November 11, 2025, including Arvind Fashions, Bliss GVS Pharma, and Edelweiss Financial Services.

Summary

BSE has approved the listing of further securities issued by seven companies under their Employee Stock Option Plans (ESOP) and Employee Stock Option Schemes (ESOS). These securities will be listed and admitted for trading on the Exchange with effect from Tuesday, November 11, 2025. The listings include companies from various sectors including fashion, pharmaceuticals, manufacturing, financial services, and technology.

Key Points

  • Total of 7 companies listing additional securities under ESOP/ESOS schemes
  • Total of 902,324 new shares being listed across all companies
  • Effective trading date: November 11, 2025
  • One company (Bliss GVS Pharma) has securities under lock-in until April 10, 2026
  • Six companies have no lock-in period restrictions
  • Face values range from Re 1 to Rs 10 depending on the company

Securities Details

Companies and Share Counts:

  1. Arvind Fashions Limited (Scrip: 542484)

    • Shares: 22,279
    • Face Value: Rs 4
    • Lock-in: None

  2. Bliss GVS Pharma Limited (Scrip: 506197)

    • Shares: 39,450
    • Face Value: Re 1
    • Lock-in: Until April 10, 2026

  3. Carborundum Universal Ltd. (Scrip: 513375)

    • Shares: 3,000
    • Face Value: Re 1
    • Lock-in: None

  4. Edelweiss Financial Services Ltd. (Scrip: 532922)

    • Shares: 367,683
    • Face Value: Re 1
    • Lock-in: None

  5. IIFL Capital Services Limited (Scrip: 542773)

    • Shares: 252,550
    • Face Value: Rs 2
    • Lock-in: None

  6. Mphasis Limited (Scrip: 526299)

    • Shares: 155,762
    • Face Value: Rs 10
    • Lock-in: None

  7. UNO Minda Limited (Scrip: 532539)

    • Shares: 61,600
    • Face Value: Rs 2
    • Lock-in: None

Regulatory Changes

No regulatory changes. This is a routine listing notification for securities issued under existing ESOP/ESOS frameworks.

Compliance Requirements

  • Trading members are informed to note the listing of these securities
  • Securities will be available for trading from November 11, 2025
  • Lock-in restrictions apply to Bliss GVS Pharma securities until April 10, 2026
  • All other securities have no trading restrictions

Important Dates

  • Notice Date: November 10, 2025
  • Listing Effective Date: November 11, 2025 (Tuesday)
  • Lock-in Expiry (Bliss GVS Pharma only): April 10, 2026

Impact Assessment

Market Impact: Minimal. These are routine ESOP/ESOS listings representing employee compensation exercises. The total number of shares (902,324) is relatively small and spread across seven companies.

Liquidity Impact: Negligible immediate impact on stock liquidity. Most shares have no lock-in period, though the quantities are modest relative to typical trading volumes.

Corporate Impact: Positive for employee retention and compensation. Reflects companies exercising standard employee benefit programs.

Investor Consideration: Marginal dilution effect on existing shareholders, but this is typical corporate governance practice for employee compensation and typically already factored into market expectations.

Impact Justification

Routine ESOP/ESOS listing with no material market impact; standard corporate action affecting employee compensation schemes